RecruitingPhase 3NCT07052903

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Studying Amyloidosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Alnylam Pharmaceuticals
Principal Investigator
Medical Director
Alnylam Pharmaceuticals
Intervention
Nucresiran(drug)
Enrollment
1250 enrolled
Eligibility
18-85 years · All sexes
Timeline
20252032

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07052903 on ClinicalTrials.gov

Other trials for Amyloidosis

Additional recruiting or active studies for the same condition.

See all trials for Amyloidosis

← Back to all trials